ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.80% | 40.22% | 59.06% | 78.13% | 78.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.80% | 40.22% | 59.06% | 78.13% | 78.29% |
| Cost of Revenue | 10.09% | 25.58% | 33.15% | 41.19% | 14.52% |
| Gross Profit | 17.01% | 56.23% | 90.84% | 141.99% | 244.24% |
| SG&A Expenses | 33.14% | 52.40% | 58.47% | 28.88% | 12.64% |
| Depreciation & Amortization | -77.46% | -87.05% | -86.63% | -84.36% | -20.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.47% | 33.08% | 39.31% | 36.89% | 12.20% |
| Operating Income | 9.18% | 59.85% | 124.99% | 356.40% | 8,387.74% |
| Income Before Tax | 11.84% | 81.78% | 296.73% | 1,332.71% | 662.72% |
| Income Tax Expenses | 55.13% | 1,000.17% | -- | -- | -- |
| Earnings from Continuing Operations | 6.73% | 51.10% | 734.15% | 1,299.96% | 603.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.73% | 51.10% | 734.15% | 1,299.96% | 603.25% |
| EBIT | 9.18% | 59.85% | 124.99% | 356.40% | 8,387.74% |
| EBITDA | 8.75% | 53.96% | 110.36% | 285.80% | 2,438.34% |
| EPS Basic | 2.76% | 45.37% | 706.02% | 1,242.98% | 582.17% |
| Normalized Basic EPS | 10.79% | 75.10% | 203.51% | 1,278.87% | 638.55% |
| EPS Diluted | 7.69% | 41.39% | 676.07% | 1,400.00% | 533.33% |
| Normalized Diluted EPS | 12.11% | 75.72% | 192.01% | 1,259.42% | 616.76% |
| Average Basic Shares Outstanding | 3.90% | 3.89% | 4.63% | 4.13% | 4.37% |
| Average Diluted Shares Outstanding | 2.66% | 3.49% | 8.82% | 4.72% | 8.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |